Myelodysplastic Syndromes (MDS) are heterogeneous, malignant disorders originating from blood stem cells that are characterized by insufficient blood cell production (cytopenia), aberrant maturation (dysplasia), inflammation and a propensity to evolve towards acute myeloid leukemia (AML). In this project, we will analyze biobanked samples from untreated MDS patients with a multi-omics approach (DNA, RNA and proteins) to investigate protein diversity from alternative splicing, characterize their influence on relevant clinical outcomes and identify potential novel disease-specific targets for treatment.